Navigation Links
Oncotest GmbH and Debiopharm Group Announce a Successful Partnership in the Identification of Biomarker Candidates
Date:4/24/2013

ons, novel combinations of anti-cancer molecules and potential biomarkers are identified using a combination of in vitro and in vivo tests with Oncotest's extensively characterized collection of more than 400 unique patient-derived tumor xenografts (PDX) propagated in nude mice. PDX are known to replicate patient tumor responses to anti-cancer drugs to a high degree. Ex vivo 3D assays are an important component of Oncotest's assay portfolio and standard panels of up to 200 PDX are offered for 3D assay campaigns. Clients benefit from Oncotest's industry leading experience.
Oncotest, based in Freiburg, Germany, was founded in 1993 by Prof. Heiner Fiebig , a clinical oncologist who pioneered the use of PDX for anti-cancer drug discovery and development. The company is focused on preclinical pharmacology of anti-cancer agents and works with large pharmaceutical and biotech companies. http://www.oncotest.de

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information
'/>"/>

SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
2. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
3. The SDS/MSA Support Group Officially Changes Name to The Multiple System Atrophy Coalition
4. Many Ginkgo Extracts Safe, Says Herbal Science Group
5. Dr. Vasquez at the Connecticut Plastic Surgery Group Now Offers the Unique Crisalix 3D Simulations for Facial Aesthetics and Breast Augmentation
6. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
7. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
8. Atlantica Group LLC to Support International "Soft-Landing" Efforts of Incubators and Accelerators
9. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
10. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
11. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... Aug. 19, 2014 A Geisinger researcher on ... for a Centers for Disease Control and Prevention (CDC) ... public health concern. Joseph Boscarino , ... of a team of researchers nominated for the Centers ... Science Award for Data Methods and Study Design. ...
(Date:8/19/2014)... KS (PRWEB) August 19, 2014 ... offer fast and cost-effective metabolite production from bioactive ... proprietary chemistry platform, the technology enables convenient and ... According to XenoTech’s Vice President of Commercial ... synthesis for assessing clinical risk can be measured ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... 2011 Verenium Corporation (Nasdaq: VRNM ), ... and commercialization of high-performance enzymes, today announced that it ... at the second annual Bright Lights Conference in New ... is the only conference with an exclusive focus on ...
... Responding quickly to the FDA,s proclaimed new limits ... Laboratories, Inc., http://www.pisgahlabs.com , files a patent ... products. Filed with the US Patent & Trademark ... is the eighteenth filing for Pisgah and represents ...
... of API analytical standards Epichem, announced today it has ... Life Sciences supplier company, AR Brown, for sales to ... in Tokyo, AR Brown is one of Japan,s largest ... have earned the reputation as a strong and reliable ...
Cached Biology Technology:Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 2Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 3Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 4Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market 2Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market 3Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 2Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 3
(Date:8/20/2014)... Huntsman Cancer Institute (HCI) at the University of Utah ... that encodes BCR-ABL, the unregulated enzyme driving the blood ... Cancer Society, nearly 6,000 new cases of CML will ... called tyrosine kinase inhibitors (TKIs), target BCR-ABL and are ... CML but control it in a way that allows ...
(Date:8/20/2014)... Tbingen, Arizona State University, the Wellcome Trust Sanger Institute ... TPH) isolated Mycobacterium pinnipedii from skeletons found ... The pathogen is a relative of the TB bacterium ... humans today. These researchers assume that seals carried the ... to sea lions was unexpected" comments Sebastien Gagneux, from ...
(Date:8/20/2014)... -- Bay Area Lyme Foundation, which aims to make ... applauds new research published in an upcoming issue of ... Diseases . The findings show that ticks that ... the year, making the threat of Lyme disease year-round. ... of Public Health (CDPH) Vector-borne Disease Section and University ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... TORONTO, Ont., June 21, 2011Researchers at St. Michael,s Hospital ... for patients with kidney failure. Cells that help protect ... home during the night than those who undergo standard daytime ... nephrologist. This is important for patients with kidney ...
... Calif., June 21, 2011 DigitalPersona, Inc. , ... today announced Sailormen, Inc. , the largest Popeye,s ... out U.are.U® Fingerprint Readers to 148 locations ... Sailormen, Inc. has found that the deployment of fingerprint ...
... Rochelle, a professor at The University of Texas at ... the Donald L. Katz Award from the Gas Processors ... during the organization,s annual convention in San Antonio and ... engineering education. , "Gary has a long history ...
Cached Biology News:New evidence of the benefits of home dialysis for kidney patients 2Popeye's Restaurant Franchisee Uses DigitalPersona Fingerprint Biometrics to Reduce Employee Fraud 2Popeye's Restaurant Franchisee Uses DigitalPersona Fingerprint Biometrics to Reduce Employee Fraud 3University of Texas at Austin professor receives Donald L. Katz Award 2
...
... PowerEase 500 Power Supply is ... It offers extensive programming capabilities ... custom methods for you to ... The simple intuitive PowerEase interface ...
... Transformation Buffer Set are convenient methods for ... for simple and highly efficient DNA transformation. ... for heat shocking and related procedures. Instead, ... adding DNA to Z-Competent cells and incubating ...
Buffer used for mitocapture assays....
Biology Products: